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Cost-eﬀ ectiveness of community-based screening and 
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Timothy B Hallett, Mark Thursz 
Summary
Background Despite the high burden of hepatitis B virus (HBV) infection in sub-Saharan Africa, absence of widespread 
screening and poor access to treatment leads to most people remaining undiagnosed until later stages of disease 
when prognosis is poor and treatment options are limited. We examined the cost-eﬀ ectiveness of community-based 
screening and early treatment with antiviral therapy for HBV in The Gambia.
Methods In this economic evaluation, we combined a decision tree with a Markov state transition model to compare 
a screen and treat intervention consisting of adult community-based screening using a hepatitis B surface antigen 
(HBsAg) rapid test and subsequent HBV antiviral therapy versus current practice, in which there is an absence of 
publicly provided screening or treatment for HBV. We used data from the PROLIFICA study to parameterise 
epidemiological, primary screening, and cost information, and other model parameter inputs were obtained from a 
literature search. Outcome measures were cost per disability-adjusted life-year (DALY) averted; cost per life-year 
saved; and cost per quality-adjusted life-year (QALY) gained. We calculated the incremental cost-eﬀ ectiveness ratios 
(ICERs) between current practice and the screen and treat intervention. Costs were assessed from a health provider 
perspective. Costs (expressed in 2013 US$) and health outcomes were discounted at 3% per year.
Findings In The Gambia, where the prevalence of HBsAg is 8·8% in people older than 30 years, adult screening and 
treatment for HBV has an incremental cost-eﬀ ectiveness ratio (ICER) of $540 per DALY averted, $645 per life-year 
saved, and $511 per QALY gained, compared with current practice. These ICERs are in line with willingness-to-pay 
levels of one times the country’s gross domestic product per capita ($487) per DALY averted, and remain robust over 
a wide range of epidemiological and cost parameter inputs.
Interpretation Adult community-based screening and treatment for HBV in The Gambia is likely to be a cost-eﬀ ective 
intervention. Higher cost-eﬀ ectiveness might be achievable with targeted facility-based screening, price reductions of 
drugs and diagnostics, and integration of HBV screening with other public health interventions.
Funding European Commission.
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Introduction
An estimated 250 million people worldwide are chronically 
infected with hepatitis B virus (HBV), which is often 
asymptomatic during the early stages of disease.1 If left 
untreated, about 25% of infected individuals will progress 
to cirrhosis or hepatocellular carcinoma, for which 
prognosis is poor. Approximately 1 million people die every 
year from HBV-related end-stage liver disease; the burden 
is concentrated in resource-poor settings, including West 
Africa, where more than 70% of cases of hepatocellular 
carcinoma in people younger than 50 years are caused by 
HBV.2 Screening, which aims to identify people with 
asymptomatic infection and oﬀ er early intervention with 
antiviral therapy, could be an important public health 
measure to prevent HBV-related morbidity and mortality.
International recommendations, including the new 
WHO guidelines, recommend treatment for chronic 
HBV infection.3 However, in practice, publicly funded 
treatment for HBV mono-infection is not available in 
sub-Saharan Africa.4 Poor infrastructure, high diagnostic 
and treatment costs, limited community awareness, and 
absence of trained health-care professionals are just a 
few of the possible contributing factors that account for 
this discrepancy. Treatment for chronic HBV infection, 
without active screening, has been shown to be cost-
eﬀ ective in many settings;5,6 however, screening studies 
have focused on high-risk target groups in high-income 
countries rather than the general population in highly 
endemic low-income countries.7 The advent of potent 
antiviral drugs such as tenofovir, now available at generic 
prices for HIV treatment but eﬀ ective in the treatment of 
both HIV and HBV, makes screening and treatment for 
chronic HBV infection potentially feasible in more low-
income and middle-income countries.
To our knowledge, this study is the ﬁ rst economic 
evaluation of a community screening and treatment 
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strategy for chronic HBV infection in a low-income or 
middle-income setting. It aims to inform decisions on 
health policy and resource allocation by presenting the 
possible costs and beneﬁ ts of improving rates of 
diagnosis and treatment of people with asymptomatic 
HBV infection in sub-Saharan Africa, a strategy that has 
so far had a very limited evidence base.
Methods
Model structure
We developed a decision tree representing the intervention 
characteristics of screening and treatment and combined 
this tree with Markov models representing the untreated 
and treated natural history of chronic HBV infection 
(appendix). We identiﬁ ed eight mutually exclusive health 
domains to represent the clinical states of the natural 
history of chronic HBV infection, in accordance with 
internationally accepted deﬁ nitions.60 These stages were 
based on HBeAg status (a serological marker representing 
high infectivity), HBV viral load, alanine aminotransferase 
concentration, and degree of liver ﬁ brosis. Transition 
parameters between health states were obtained from 
results of a literature review (table 1). The model was 
created in Tree Age Pro 2014 and was used to simulate 
disease progression in the cohorts, in annual cycles for a 
period of 40 years. We used data from the PROLIFICA 
study to parameterise epidemiological, screening, and cost 
information, and other model parameter inputs were 
obtained from a literature search.
Study setting
The multicentre PROLIFICA study assessed the 
feasibility of a screen and treat HBV intervention 
programme across the western part of The Gambia 
(NCT02129829). Study methods are described in detail 
elsewhere.61 The study was approved by The Gambia 
Government/MRC Joint Ethics committee.
Comparator strategies 
In this economic evaluation, we compared the screen and 
treat intervention versus current practice. Our baseline 
strategy reﬂ ects current practice—speciﬁ cally, the absence 
of publicly provided screening or treatment for HBV in 
The Gambia. Therefore, costs for this strategy reﬂ ect those 
incurred if and when patients present at the later stages of 
disease because of morbidity from cirrhosis and 
hepatocellular carcinoma, when patient outcomes are also 
poorer.
For the screen and treat intervention, community-
based screening consisted of initial community 
sensitisation, door-to-door household registration of 
eligible participants (aged ≥30 years), and testing for 
hepatitis B surface antigen (HBsAg; a marker of being 
infected with HBV), by use of a rapid point-of-care test.61 
This part of the intervention was carried out by ﬁ eld 
workers. Individuals with a positive test result were 
oﬀ ered outpatient review for diagnostic assessment 
including routine blood tests, HBV viral load, screening 
for co-infection with HIV, hepatitis C virus (HCV), or 
hepatitis delta virus (HDV), liver ultrasound scan, and 
transient elastography (FibroScan) for assessment of 
liver ﬁ brosis. Patients meeting European Association for 
the Study of the Liver (EASL) criteria60 for treatment were 
prescribed tenofovir monotherapy. Standard monitoring 
was done in accordance with international guidelines 
and we assumed lifelong treatment. We assumed that 
there was no resistance to tenofovir13 and that antiviral 
treatment would halt disease progression (if patients 
were completely adherent to treatment). However, for 
individuals with already established cirrhosis, there 
Research in context
Evidence before this study
We searched PubMed for articles published before 
September, 2015, with terms incorporating “Hepatitis B”, 
“HBV”, or “CHB” and “Cost*” or “Economic” and “Screen*”, 
“Test*”, or “Diagnosis”. We found no previous studies describing 
costs or cost-eﬀ ectiveness of community-based screening for 
hepatitis B virus (HBV) infection in low-income or 
middle-income countries. Research in high-income countries 
included two previous community-based studies of cost-
eﬀ ectiveness of screening, and further studies of screening in 
groups classiﬁ ed as high risk, including immigrant populations, 
many of which were based on hypothetical cohorts, rather than 
real-life screening data.
Added value of this study
To our knowledge, this study is the ﬁ rst to investigate the cost-
eﬀ ectiveness of adult screening and treatment for HBV at the 
community level in a low-income or middle-income setting. 
Furthermore, the study includes real-life cost and eﬀ ectiveness 
parameter data from a large-scale screening and treatment 
programme in The Gambia. The model incorporates clinically 
salient features and is unique in presenting results using three 
diﬀ erent outcome measures.
Implications of all the available evidence
Ambitious targets for improving testing and treatment for HBV 
form part of the recent WHO Global Health Sector Strategy for 
viral hepatitis. Evidence on how to achieve these targets will be 
needed to help guide national policies. Screening and 
treatment for hepatitis B has been shown to be a feasible and 
cost-eﬀ ective intervention in The Gambia and should be 
considered as a public health strategy to reduce mortality and 
morbidity from cirrhosis and liver cancer. Our study helps to 
inform such decisions, and highlights the need for further 
similar analyses in other highly endemic countries. 
See Online for appendix
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Base-case 
value
Deterministic 
range
PSA 
distribution
PSA parameters Source* Further description
Intervention costs
One-oﬀ  activity
Screening cost per person 
(US$)
7·43 3·72–14·9 Gamma† a=100; λ=13·4 Primary data, 
PROLIFICA
··
Initial assessment visit (US$) 120 60–200 Gamma ±20% range for 
each component 
part
Primary data, 
PROLIFICA
Initial assessment visit includes routine blood tests, virology, 
ultrasound scan, transient elastography (FibroScan), and 
staﬀ  costs
Annual management
Drug treatment (US$) 48 24–207 Point 
estimate
·· Ref 8 Treatment consisted of antiviral therapy with daily tenofovir 
at generic price
Monitoring on treatment (US$) 36·88 30–44 Gamma ±20% range for 
each component 
part
Primary data, 
PROLIFICA
Monitoring is done every 6 months in the treated stages of 
chronic HBV infection
Monitoring not on treatment 
(US$)
15·77 13–32 Gamma ±20% range for each 
component part
Primary data, 
PROLIFICA
Monitoring is done yearly in the untreated stages of chronic 
HBV infection
Costs of hospital admission
Cost per day of hospital stay (US$) 6·66 ·· ·· ·· Ref 9 WHO-CHOICE values are given minus drug and laboratory 
costs; therefore, we have multiplied by a factor of two to 
account for these
Average length of hospital stay 
(days)
7·15 ·· ·· ·· Ref 9 ··
Cost per hospital admission (US$) 47·24 ·· Gamma† a=3·57; λ=0·0756 Ref 9 Average cost per hospital admission in stages of 
compensated cirrhosis, decompensated cirrhosis, and 
hepatocellular carcinoma is equal to the average length of 
stay multiplied by the cost per day of hospital stay
Number of hospital admissions 
per year for compensated 
cirrhosis
2 ·· Uniform low=0; high=4 Assumption ··
Number of hospital admissions 
per year for decompensated 
cirrhosis
3 ·· Uniform low=0; high=6 Assumption ··
Number of hospital admissions 
per year for hepatocellular 
carcinoma
3 ·· Uniform low=0; high=6 Assumption ··
Average annual cost of hospital 
admission for compensated 
cirrhosis (US$)
95·24 0–190 ·· ·· Based on above Annual cost of hospital admission in each stage is equal to 
the cost per hospital admission multiplied the number of 
hospital admissions per year
Average annual cost of hospital 
admission for decompensated 
cirrhosis (US$)
142·86 48–286 ·· ·· Based on above Annual cost of hospital admission in each stage is equal to 
the cost per hospital admission multiplied the number of 
hospital admissions per year
Average annual cost of hospital 
admission for hepatocellular 
carcinoma (US$)
142·86 48–286 ·· ·· Based on above Annual cost of hospital admission in each stage is equal to 
the cost per hospital admission multiplied the number of 
hospital admissions per year
Epidemiological parameters‡
HBsAg prevalence (%) 8·8% 0–15% Point 
estimate
·· PROLIFICA ··
Screening uptake (%) 68·9% 63–97% Point 
estimate
·· PROLIFICA (ref 10)‡ Intervention coverage reported in the PROLIFICA study was 
used as a proxy for uptake of screening, as we can assume all 
eligible individuals were oﬀ ered screening, given the study 
design
Linkage to care (%) 81·3% 62–95% Point 
estimate
·· PROLIFICA (ref 11)‡ Deﬁ ned as attendance at the ﬁ rst clinic appointment after 
being tested HBsAg positive in the community
Adherence to treatment in 
year 1 (%)
80·9% 77–95% Point 
estimate
·· PROLIFICA (ref 12)‡ Adherence to antiviral therapy in the ﬁ rst year of treatment
Annual rate of drop-out of 
treatment after year 1 (%)
2% 1–5% Point 
estimate
·· Assumption Yearly drop-out rate from second year of antiviral treatment 
onwards
Annual resistance to treatment (%) 0% 0–2%
(after year 6)
Point 
estimate
·· Ref 13 ··
(Table 1 continues on next page)
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Base-case 
value
Deterministic 
range
PSA 
distribution
PSA parameters Source* Further description
(Continued from previous page)
Annual risk of developing 
hepatocellular carcinoma in 
individuals with compensated 
cirrhosis on antiviral therapy (%)
0·5% 0–1% Beta a=0·747; b=149 Refs 14, 15 ··
Annual risk of developing 
hepatocellular carcinoma in 
individuals with decompensated 
cirrhosis on antiviral therapy (%)
1% 0–4·4% Beta a=0·808; b=80·0 Refs 14, 15 ··
Sensitivity of HBsAg POC test (%) 88·5% 85·1–98·2% Point 
estimate
·· PROLIFICA 
(refs 16,17)‡
Patients with false-positive results on screening are seen in 
clinic and have full diagnostic assessment including 
conﬁ rmatory HBsAg serology; they are then discharged from 
care and do not receive unnecessary treatment. Patients 
with false-negative results are those who tested HBsAg 
negative at screening, and are therefore not followed up in 
clinic and do not receive treatment; they progress in the 
model as per the untreated natural history of HBV
Speciﬁ city of HBsAg POC test (%) 100% 99·03–100% Point 
estimate
·· PROLIFICA 
(refs 16,17)‡
See previous row for description of false-positive and 
false-negative cases
Start age of cohort (years) 38 15–50 Point 
estimate
·· PROLIFICA Screening was oﬀ ered to all individuals older than 30 years; 
however, the start age of our modelled cohort was 38 years 
to correspond with the median age of HBV-positive patients 
screened in the community
Discount rate: costs (%) 3% 0–6% Point 
estimate
Refs 18, 19 ··
Discount rate: health 
outcomes (%)
3% 0–6% Point 
estimate
Refs 18, 19 ··
Annual disease transition rates§
From immune tolerant to:
Immune reactive 0·1 0·03–0·2 Beta a=5·063; b=45·57 Refs 20–22 ··
Hepatocellular carcinoma 0·003 0–0·006 Beta a=3·985; 
b=1324·35
Assumption ··
From immune reactive to:
Inactive carrier 0·05735 0·0458–0·06882 Beta a=11·971; 
b=196·76
Refs 23,24 ··
HBeAg-negative chronic HBV 0·005 0–0·05 Beta a=0·154; b=30·69 Assumption ··
Compensated cirrhosis 0·0277 0·01–0·054 Beta a=6·138; b=215·45 Refs 25–31 ··
Hepatocellular carcinoma 0·0065 0·0027–0·01 Beta a=12·596; 
b=1925·30
Refs 26–28, 32–35 ··
From inactive carrier to:
HBeAg-negative chronic HBV 0·0268 0·0155–0·0471 Beta a=11·173; 
b=405·74
Refs 24, 36–41 ··
Hepatocellular carcinoma 0·00065 0–0·001 Beta a=0·057; b=94·89 Ref 42 ··
HBsAg negative 0·01 0·0097–0·0226 Beta a=17·146; 
b=1257·65
Refs 23, 38, 39, 43 ··
From HBeAg-negative chronic 
HBV to:
Compensated cirrhosis 0·04 0·01–0·052 Beta a=11·173; 
b=300·92
Refs 25–31, 37, 43, 44 ··
Hepatocellular carcinoma 0·00616 0·0027–0·01 Beta a=11·300; 
b=1824·50
Refs 43 ··
From compensated cirrhosis to:
Decompensated cirrhosis 0·039 0·032–0·046 Beta a=2·848; b=70·18 Refs 35, 45–47 ··
Hepatocellular carcinoma 0·0366 0·008–0·08 Beta a=3·947; b=103·88 Refs 20, 28, 32, 35, 
46, 48–56
··
Death 0·039 0·039–0·507 Beta a= 0·270; b= 6·66 Ref 57 ··
From decompensated cirrhosis to:
Hepatocellular carcinoma 0·0376 0·023–0·071 Beta a=9·411; b=240·88 Refs 45, 48–52, 58 ··
(Table 1 continues on next page)
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remained an ongoing risk of developing hepatocellular 
carcinoma despite antiviral therapy.14,15
Cohort characteristics
Although screening was oﬀ ered to all individuals living 
in study areas who were aged 30 years or older, the start 
age of our modelled cohort was 38 years, corresponding 
with the median age of HBV-positive patients screened 
in the community, in an attempt to avoid overestimation 
of health beneﬁ ts. We assumed that all individuals 
oﬀ ered screening had not been vaccinated against HBV, 
because the universal infant vaccination programme 
only began in 1990 in The Gambia.2 The starting 
distribution of the infected cohort across diﬀ erent clinical 
states was based on PROLIFICA data (appendix). We 
assumed that natural history and cost parameters were 
independent of age and sex, but applied an age-structured 
Gambia-speciﬁ c mortality rate.62
Costs
Costs were assessed from a health provider perspective, 
and were based on the PROLIFICA study budget, public 
health facility activity data, and interviews with key health 
personnel regarding time and resource use. Costs 
consisted of personnel, equipment, materials, and 
maintenance. The cost components of the screen and 
treat intervention included one-oﬀ  costs for screening of 
US$7·43 per person oﬀ ered screening and initial 
diagnostic assessment cost of $120 per patient. Annual 
costs were $48 for drugs, $36·88 for monitoring on 
antiviral therapy, and $15·77 for monitoring if not on 
antiviral therapy (table 1).
We used data from WHO-CHOICE to estimate costs of 
hospital admission in The Gambia.9 All costs are 
expressed in 2013 US$. Future costs and health outcomes 
were discounted at 3% per year, as per WHO guidelines 
and Gates Reference Case.18,19
Outcome measures
We present three outcome measures to allow for greater 
comparability with existing literature and to acknowledge 
that each one has limitations: cost per disability-adjusted 
life-year (DALY) averted; cost per life-year saved; and cost 
per quality-adjusted life-year (QALY) gained. When 
available, we used disability weights from the Global 
Burden of Disease Study 2010,59 and approximated from 
other diseases if liver-speciﬁ c weights were not available. 
Health utilities are not well deﬁ ned for HBV in low-
income and middle-income countries, but we used mean 
cross-country utilities from a multi-country study by Levy 
Base-case 
value
Deterministic 
range
PSA 
distribution
PSA parameters Source* Further description
(Continued from previous page)
Death 0·314 0·043–0·57 Beta a=3·583; b=7·83 Ref 57 ··
From hepatocellular carcinoma to:
Death 0·5 0·4–1 Beta a=5·056; b=5·06 Ref 57 ··
Disability weights¶
Immune tolerant 0·053 ·· Beta a=20·13; b=359·73 GBD 201059 Disability weight for “HIV receiving ARV” was used as proxy
Immune reactive 0·053 ·· Beta a=20·13; b=359·73 GBD 201059 Disability weight for “HIV receiving ARV” was used as proxy
Inactive carrier 0·053 ·· Beta a=20·13; b=359·73 GBD 201059 Disability weight for “HIV receiving ARV” was used as proxy
HBeAg-negative chronic HBV 0·053 ·· Beta a=20·13; b=359·73 GBD 201059 Disability weight for “HIV receiving ARV” was used as proxy
Compensated cirrhosis 0·127 ·· Beta a=10·02; b=68·90 GBD 201059 Disability weight for “Decompensated cirrhosis of the liver” 
was used as proxy (lower CI used)
Decompensated cirrhosis 0·194 ·· Beta a=21·67; b=90·05 GBD 201059 Disability weight for “Decompensated cirrhosis of the liver” 
was used 
Hepatocellular carcinoma 0·519 ·· Beta a=18·10; b=16·77 GBD 201059 Disability weight for “Terminal phase: without medication 
(for cancers, end-stage kidney or liver disease)” was used
Treated immune reactive 0·053 ·· Beta a=20·13; b=359·73 GBD 201059 Disability weight for “HIV receiving ARV” was used as proxy
Treated HBeAg-negative chronic 
HBV
0·053 ·· Beta a=20·13; b=359·73 GBD 201059 Disability weight for “HIV receiving ARV” was used as proxy
Treated compensated cirrhosis 0·053 ·· Beta a=20·13; b=359·73 GBD 201059 Aassumed returns to same disability weight as untreated 
chronic HBV stages
Treated decompensated cirrhosis 0·127 ·· Beta a=10·02; b=68·90 GBD 201059 Assumed returns to same disability weight as untreated 
chronic HBV stages
See appendix for starting state distributions of chronic HBV infection and for health utilities used for quality-adjusted life-year calculations. ARV=antiretroviral. HBeAg=hepatitis B envelope antigen. 
HBsAg=hepatitis B surface antigen. HBV=hepatitis B virus. POC=point-of-care. PSA=probabilistic sensitivity analysis. PROLIFICA=Prevention of Liver Fibrosis and Cancer in Africa. Ref=reference number. *If more 
than one reference is given, the ﬁ nal value represents a summary value. †In the gamma distributions, the λ parameter is equal to mean/SD². ‡The references provided represent the sources of the parameter 
ranges used in the sensitivity analyses. §For transition rates used from the review by Lin and colleagues,57 the original articles are individually referenced. ¶The equivalent category in the Global Burden of Disease 
Study 2010,59 which was used for the disability weight of each of these health states, is described.  
Table 1: Main model parameters
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and colleagues63 for our base-case QALY. Life-years 
represent an objective measure, but do not take into 
account morbidity.
Measurement of cost-eﬀ ectiveness
We calculated an incremental cost-eﬀ ectiveness ratio 
(ICER) between current practice and the screen and 
treat intervention, which was deﬁ ned as (costscreen and treat 
intervention–costcurrent practice)/(eﬀ ectivenessscreen and treat intervention–
eﬀ ectivenesscurrent practice). A new intervention is often 
deemed cost-eﬀ ective if the ICER is below a willingness-
to-pay (WTP) threshold. However, these thresholds and 
their use are contested, especially in low-income and 
middle-income countries where various thresholds have 
been suggested, including multiples of a country’s gross 
domestic product (GDP) per capita64 and a World Bank 
threshold of $240 per DALY averted.65,66 We therefore 
present a range of WTP thresholds to allow the decision 
maker to put the results of our study into the context of 
these various thresholds—namely, one times GDP per 
capita ($487),67 three times GDP per capita ($1460), and 
a more stringent World Bank threshold of $240 per 
DALY averted.
Sensitivity analysis
We performed a series of one-way deterministic sensitivity 
analyses that varied the parameters individually over 
plausible ranges to test the robustness of our ﬁ ndings 
and to identify key uncertainties and data collection 
priorities (table 1). Multiple combinations of health utility 
values were also explored in the sensitivity analysis 
(appendix). We did a multivariate probabilistic sensitivity 
analysis to characterise the overall combined uncertainty 
of all the model parameters using second order Monte 
Carlo simulations. Distributions for parameter values 
were speciﬁ ed by a gamma distribution for costs (range of 
±20%) and beta distribution for probabilities (range taken 
from published literature, or if unavailable ±0·2, 
constrained between 0 and 1). Uncertainty in the model is 
presented in a cost-eﬀ ectiveness acceptability curve.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to the data in the study and had ﬁ nal responsibility 
for the decision to submit for publication.
Results
The projected total health beneﬁ t that a round of 
screening will impart on this cohort of 8170 people 
compared with no screening is an additional 498 DALYs 
averted, 417 life-years gained, or 526 QALYs saved.
The screen and treat intervention has ICERs of 
$540 per DALY averted, $645 per life-year saved, and $511 
per QALY gained, compared with current practice 
(table 2). The cost per DALY averted compares favourably 
to a three times GDP per capita threshold in The Gambia 
Average per person ICER
Cost (US$) Life-years 
saved
QALY DALY US$ per DALY 
averted
US$ per 
QALY gained
US$ per life-
year saved
Current practice 11·15 19·84 16·98 4·28 ·· ·· ··
Screen and treat 
intervention
44·08 19·89 17·04 4·22 540 511 645
DALY=disability-adjusted life-year. ICER=incremental cost-eﬀ ectiveness ratio. QALY=quality-adjusted life-year.
Table 2: Summary results for each strategy 
Figure 1: Tornado diagram showing one-way sensitivity analyses of parameters that aﬀ ect the ICER
The ﬁ rst nine parameters aﬀ ect the ICER by greater than US$100 over the ranges speciﬁ ed. The bottom three parameters aﬀ ect the ICER to a lesser extent, but are 
included because they are important for programmatic implementation. Parameter categories are grouped by colour: purple represents costs, green represents 
transition rates, and red represents patient behaviours. The values representing the lower and higher ranges over which the parameter was varied are shown in 
parentheses. The dashed vertical black line represents the base case value. DALY=disability-adjusted life-year. ICER=incremental cost-eﬀ ectiveness ratio. 
*Treatment adherence refers to adherence in the ﬁ rst year, when the subsequent yearly drop-out rate was kept constant at 2% per year. 
Drug cost ($24–207)
HBeAg-negative chronic hepatitis B to compensated cirrhosis (0·01–0·052)
Cost of screening ($3·72–14·9)
Inactive carrier to HBeAg-negative chronic hepatitis B (0·0155–0·0471)
Cost of annual monitoring untreated ($13–32)
Compensated cirrhosis to death (0·039–0·507)
Cost of initial diagnostic assessment ($60–200)
Cost of annual hospital admission for compensated cirrhosis ($0–190)
Compensated cirrhosis to hepatocellular carcinoma (0·008–0·08)
Screening uptake (63–97%)
Treatment adherence* (77–95%)
Linkage into care (62–95%)
450400 500 550 600 650 700 750 800 850 900 950 1000 1050 1100
ICER (US$ per DALY averted)
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and is in line with a one times GDP per capita threshold, 
implying that the screening and treatment strategy is 
likely to be cost-eﬀ ective. However, if the highly 
conservative World Bank threshold of $240 per DALY 
averted is used, this strategy is not cost-eﬀ ective.
One way-sensitivity analyses showed that the ICER 
remained below three times GDP per capita per DALY 
averted, irrespective of outcome measure, for most 
plausible ranges of parameters (ﬁ gure 1). Here, we 
discuss the parameters that had most eﬀ ect on the 
ICERs, were most uncertain, or are important for 
programmatic implementation.
Varying HBsAg prevalence to 10%, 5%, 2%, and 1% 
increased the ICER to $526, $633, $955, and $1492 per 
DALY averted, respectively, with a sharp increase in the 
ICER at a prevalence lower than 2% (ﬁ gure 2). When the 
age of the cohort screened was increased from 15 to 
50 years, the ICER increased from $443 to $824 per DALY 
averted.
A two-fold or three-fold increase in the cost of 
community screening per person from the baseline of 
$7·43 increased the ICER to $662 or $784 per DALY 
averted, respectively. The generic price of tenofovir 
available for HIV programmes in The Gambia of $48 per 
year8 was used for the base case, but increasing the 
drug price to $207, which represents the current 
pharmaceutical price of tenofovir oﬀ ered to countries in 
sub-Saharan Africa,68 increased the ICER to $1064 per 
DALY averted. A reduction in drug cost by half would 
reduce the ICER to $461 per DALY averted.
Our baseline rate of treatment adherence in the ﬁ rst 
year was 80·9% (recorded in the PROLIFICA study) and 
varying this between 77% to 95% (while maintaining a 
subsequent treatment drop-out rate of 2% per year) 
changed the ICER by $32, from $515 to $547 per DALY 
averted. Similarly, when screening uptake was varied 
over a wide range between 63% and 97%, which is in 
broad agreement with the ranges seen in the 
Demographic and Health Surveys of HIV screening in 
sub-Saharan Africa,10 the eﬀ ect on the ICER was only $46. 
Varying linkage to care (deﬁ ned here as attendance to 
ﬁ rst outpatient consultation) between 62% and 95% also 
had only a small eﬀ ect on the ICER ($13).
The natural history transition parameter with the 
greatest eﬀ ect on the ICER was the rate of progression 
from HBeAg-negative chronic HBV infection to 
compensated cirrhosis. Changing this from 0·01 to 
0·052 moved the ICER from $458 to $824 per DALY 
averted. The next most inﬂ uential transition rates were 
from inactive carrier to HBeAg-negative chronic 
HBV infection, compensated cirrhosis to death, and 
compensated cirrhosis to hepatocellular carcinoma, 
which aﬀ ected the ICERs by $183, $130, and $102 per 
DALY averted, respectively.
The use of diﬀ erent health utilities for QALY 
calculations gave a range of ICERs from $307 to $627 per 
QALY gained, the lowest ICER when utilities speciﬁ c to 
China (with a standard gamble technique)63 were used 
and the highest ICER when utilities from Singapore 
(with EuroQol-5D technique)69 were used (appendix). 
Sensitivity analysis on the discount rate for costs and 
health beneﬁ ts showed an ICER as low as $221 per DALY 
averted when costs were discounted at 6% and health 
beneﬁ ts undiscounted (appendix, Table S4).
The following parameters representing eﬀ ectiveness of 
treatment had minimal eﬀ ect (<$20) on the ICER: 
varying resistance to treatment between 0·5% to 2% per 
year after 6 years of treatment initiation, varying failure 
of reduction in disease progression on antiviral treatment 
between 0 to 2% per year, and varying the continued 
annual risk of development of hepatocellular carcinoma 
for individuals with cirrhosis on antiviral therapy, 
between 0 to 2% per year for compensated cirrhosis and 
0 to 4% per year for decompensated cirrhosis.
For 2000 Monte-Carlo simulations, mean cost was 
$44·70 (95% CI 44·39–45·00) for the screen and treat 
intervention and $12·45 (95% CI 12·00–12·91) for 
current practice. Mean DALYs were 4·215 (95% CI 
4·213–4·217) for the screen and treat intervention and 
4·27 (95% CI 4·268–4·272) for current practice. Mean 
ICER was $621 (95% CI 612·8–629·6) per DALY averted 
(see appendix for ICER scatter plot).
The cost-eﬀ ectiveness acceptability curve in ﬁ gure 3 
represents the probability that the new intervention will 
be cost-eﬀ ective over a range of decision makers’ WTP 
thresholds per additional DALY averted. At a WTP 
threshold of $1460, there is a 99·7% probability that the 
screening and treatment strategy will be cost-eﬀ ective; 
this probability reduces to 95%, 20%, and <1% if the 
WTP threshold is $974, $487, or $240, respectively.
Figure 2: Eﬀ ect of varying HBsAg prevalence on incremental cost-eﬀ ectiveness ratio
The boundaries of hepatitis B virus endemicity categories are marked by dashed green lines: low (HBsAg prevalence 
<2%), low-intermediate (2–5%), high-intermediate (5–8%), and high (>8%). The baseline HBsAg prevalence in The 
Gambia is represented by a solid grey line. HBsAg=hepatitis B surface antigen. DALY=disability-adjusted life-year.
0·5 1·5 2·5 3·5 4·5 5·5 6·5 7·5 8·5 9·5 10·5 11·5 12·5 13·5 14·5
0
200
Low
Low-
intermediate High-
intermediate
High
Baseline 8·8%
Screen and treat
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
In
cr
em
en
ta
l c
os
t-
eﬀ
ec
tiv
en
es
s r
at
io
 (U
S$
 p
er
 D
AL
Y)
HBsAg prevalence (%)
Articles
e575 www.thelancet.com/lancetgh   Vol 4   August 2016
The modelled HBV-negative, untreated HBV-positive, 
and treated HBV-positive cohorts had median survival 
ages of 70 years, 62 years, and 69 years, respectively. This 
ﬁ nding is consistent with the average life expectancy at 
age 30 years in The Gambia of 68 years,62 and the 
assumption that treatment for chronic HBV infection 
restores a near normal life expectancy. This concordance 
adds strength to the validity of the model.
Discussion
Screening and treatment for HBV in The Gambia, where 
the adult HBsAg prevalence is 8·8%, has ICERs of 
$540 per DALY averted, $645 per life-year saved, and 
$511 per QALY gained, compared with current practice. 
Whether this intervention represents a cost-eﬀ ective 
strategy must be judged in light of the WTP threshold 
adopted. The screen and treat intervention remains well 
below the commonly used benchmark WTP threshold of 
less than three times the country’s GDP per capita. 
However, because the use of this high threshold is 
increasingly questioned, we are also able to show that the 
ICERs remain in line with a much more stringent criteria 
of one times GDP per capita. Uncertainty exists around 
the chance that such an intervention will be cost-eﬀ ective 
at lower WTP thresholds. Low screening costs, highly 
eﬀ ective and relatively low cost antiviral therapy at generic 
price, and only a small proportion of people requiring 
antiviral therapy help drive the cost-eﬀ ectiveness of the 
screening and treatment strategy. However, these factors 
have to be balanced against lifelong treatment and the 
fact that a high proportion of individuals with chronic 
HBV infection will survive without treatment. Recent 
trials are showing promising results with ﬁ nite treatment 
courses in some patient groups,70 and this could help 
increase cost-eﬀ ectiveness further.
Existing economic evaluations of HBV interventions in 
low-income and middle-income countries focus on 
prevention of HBV infection through vaccination. To our 
knowledge, our study is the ﬁ rst to assess the cost-
eﬀ ectiveness of active population-level screening and 
treatment for HBV in a low-income or middle-income 
setting, using primary data from a large community-
based implementation study in The Gambia. 
Furthermore, our model is unique in incorporating all 
stages of chronic HBV, thereby taking into account the 
dynamic natural history of chronic HBV infection and 
allowing separation into treated and monitored 
categories, which have diﬀ ering associated costs and 
outcomes. Although the paucity of data in sub-Saharan 
Africa can make accurate cost-eﬀ ectiveness analyses 
challenging, sensitivity analyses have shown that the 
intervention remains cost-eﬀ ective across a wide range of 
parameter inputs and WTP thresholds.
The cost of community-based HBV screening falls at the 
lower end of the broad range of community-based HIV 
screening costs in sub-Saharan Africa presented in a 
systematic review by Suthar and colleagues (cost per 
person tested $2·45–33·54).71 Despite being perceived as a 
resource-intensive and labour-intensive strategy, in our 
study screening costs represented only 3–5% of the overall 
costs of HBV assessment and annual treatment and 
monitoring costs. Furthermore, costs are likely to be 
overestimated in our study because of ﬁ eld teams dedicated 
entirely to HBV screening as it formed part of a research 
programme. Integration of HBV screening with testing for 
other diseases such as hepatitis C virus or HIV could 
potentially reduce these costs further. Understanding how 
the quality of the intervention outside trial settings will 
impact costs and eﬀ ects will be essential.
Downstream costs of diagnosis, antiviral therapy, and 
monitoring represent a larger proportion of the total 
costs than the screening part of the intervention. Generic-
price tenofovir ($48) was used for our analysis, but a 
recent study has shown that entecavir, which is due to 
come oﬀ  patent in 2017, can be manufactured for a lower 
cost of $36,72 and could be an alternative cost-eﬀ ective 
therapy to tenofovir. If The Gambia had to purchase 
tenofovir at the current pharmaceutical price of $207 
oﬀ ered to countries in sub-Saharan Africa, this would 
substantially decrease cost-eﬀ ectiveness.68
Prevalence of chronic HBV infection can be divided into 
regions of low (<2%), low-intermediate (2–5%), high-
intermediate (5–8%), and high (>8%) endemicity.1 
Although The Gambia is classiﬁ ed as a highly endemic 
country, our analysis shows that community screening and 
treatment remains below three times GDP per capita per 
DALY averted, even at an HBV prevalence as low as 1·5%. 
Figure 3: Cost-eﬀ ectiveness acceptability curve
This ﬁ gure represents the probability that the screen-and-treat intervention will be cost-eﬀ ective over a range of 
willingness-to-pay (WTP) thresholds per disability-adjusted life-year (DALY) averted. The dashed lines represent 
diﬀ erent WTP thresholds that can be applied to The Gambia: US$1460 (represents three times the gross domestic 
product [GDP] per capita of The Gambia), $974 (represents two times the GDP per capita of The Gambia), 
$487 (represents one times the GDP per capita of The Gambia), and $240 (World Bank threshold).
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This ﬁ nding has implications for the decision of whether 
to oﬀ er widescale screening in the post-vaccination era, in 
which the overall prevalence of chronic HBV carriage has 
begun to decrease,73 and for policy makers considering the 
potential cost-eﬀ ectiveness of similar interventions in 
neighbouring countries with diﬀ erent HBV prevalence 
patterns.
Although increased uptake of interventions and patient 
engagement are needed to maximise health gains, in our 
study, uptake of screening, linkage to care, and adherence 
to therapy were not big drivers of cost-eﬀ ectiveness. Our 
baseline adherence of 80·9%, although higher than the 
reported adherence of 77% to HIV treatment in sub-
Saharan Africa,12 is lower than the reported adherence of 
87·8% to HBV treatment in North America.74 Our base-
case estimate of 81·3% potentially overestimates linkage 
to care in routine practice, because it was measured within 
a research study that provided reimbursement of 
transportation fees, clinics held in rural sites to facilitate 
access to treatment, active reminders about appointments, 
and good sensitisation and counselling of screened 
participants. However, variations in these parameters had 
little eﬀ ect on cost-eﬀ ectiveness because low rates reduce 
both the impact, as well as the costs, which scale together. 
These losses and frailties are similar to what is seen in the 
HIV care cascade.
Our model is of a static cohort and assumes homogeneity 
of the population with respect to age and sex, rather than a 
dynamic transmission model. The model therefore 
potentially underestimates the impact and cost-
eﬀ ectiveness of treatment, to the extent that treatment can 
reduce transmission in the population, especially through 
prevention of mother-to-child transmission by antiviral 
therapy. However, because only a small proportion of 
adults in The Gambia are HBeAg-positive, suggesting 
lower infectivity risk (which is consistent with data from 
other regions in sub-Saharan Africa), this extra beneﬁ t 
might be limited.75
A health provider perspective was used in this study, 
hence household costs of accessing screening and 
treatment were excluded. In a setting in which most 
people die at home, and end-of-life costs are borne by 
family members acting as caregivers, a societal perspective 
analysis would likely show a higher cost-eﬀ ectiveness of 
the intervention. Furthermore, in The Gambia, where the 
median age of patients diagnosed with hepatocellular 
carcinoma is 40 years,76 people of working age are often 
aﬀ ected; thus, the economic impact is potentially greater 
to the household and society.
Although care must be taken before generalising the 
results of this study to other regions in sub-Saharan 
Africa, the fact that our model results were robust over a 
wide range of HBV prevalence, transition probabilities, 
and cost parameters suggests that screening and 
treatment strategies should be considered in other 
countries. Direct economic comparison between 
countries and across disease areas can help put our 
results into context, but should be interpreted with 
caution. Our ﬁ ndings suggest that the cost-eﬀ ectiveness 
of a screening and treatment strategy for HBV is 
comparable to other interventions in The Gambia—for 
example, the introduction of the pneumococcal vaccine.77 
A unique feature of HBV screening is that, when 
combined with vaccination, it only requires once-a-
lifetime testing, which contrasts with HIV, where a 
negative individual still remains at risk of reinfection.
Finally, although the screen and treat intervention was 
found to lie within cost-eﬀ ective thresholds, it must be 
recognised that the WTP threshold is a theoretical one, 
especially in low-income and middle-income countries, 
to indicate whether an intervention should be entitled to 
be set as a priority in the health-care agenda. However, 
aﬀ ordability and how the intervention will be funded 
(whether by governments, out-of-pocket, insurance 
systems, or external donor funding), in addition to cost-
eﬀ ectiveness, need to be considered before an inter-
vention is adopted on a national level.
Poor access to testing and antiviral treatment remains a 
major barrier to reducing morbidity and mortality from 
HBV-related disease in sub-Saharan Africa. Our analysis 
has shown that community-based screening and 
treatment for chronic HBV infection is likely to be cost-
eﬀ ective if generic-priced tenofovir is used, which is 
currently only available for HIV treatment programmes 
in sub-Saharan Africa. Furthermore, integration of HBV 
screening with screening for other diseases, using the 
already established infrastructure for addressing HIV in 
sub-Saharan Africa, as well as simplifying diagnostic 
assessment and monitoring, might make this an even 
more cost-eﬀ ective intervention. The combination of 
vaccination, screening, and treatment raises the 
possibility of advancing the date of elimination of HBV-
related morbidity and mortality as a public health threat.78
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